Stockscreener 앱 받기
67.12
3.02%
-2.09
시간 외 거래:
67.10
-0.02
-0.03%
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know - Yahoo Finance
Halozyme Therapeutics Q1 2026 Earnings Review | HALO StockNews and Statistics - IndexBox
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO) - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Upgraded by Wall Street Zen - MarketBeat
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook - Yahoo Finance
Morgan Stanley Smith Barney files Form 144 (NASDAQ: HALO) to sell 14,700 shares - Stock Titan
A Look At Halozyme Therapeutics (HALO) Valuation After Q1 Growth, GSK ENHANZE Deal And US$1b Buyback - Sahm
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up - MSN
Arbejdsmarkedets Tillaegspension Makes New Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme outlines ENHANZE royalties exceeding $1B in 2026 while launching a new $1B buyback - MSN
Halozyme appoints Darren Snellgrove as CFO - MSN
Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75 - Moomoo
Halozyme Therapeutics (HALO) Q1 EPS Rebound Tests Bearish Margin Compression Narrative - Sahm
HALO Stock Chart | HALOZYME THERAPEUTICS INC (NASDAQ:HALO) - ChartMill
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 20,000 Shares of Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Helen Torley Sells 10,000 Shares - MarketBeat
Halozyme CEO Helen Torley sells $3.43m in stock By Investing.com - Investing.com Nigeria
Halozyme CEO Helen Torley sells $3.43m in stock - Investing.com
Halozyme (HALO) CEO Torley exercises 50K options and sells 50K shares under 10b5-1 plan - Stock Titan
(HALO) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Halozyme Therapeutics Earnings: What To Look For From HALO - Yahoo Finance UK
Halozyme Therapeutics (HALO) Announces Global Collaboration and License Agreement With GSK - Insider Monkey
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $93 - Moomoo
Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Cuts Target Price to $66.41 - Moomoo
HALO Stock Jumps After Earnings Beat And $1B Buyback - StocksToTrade
Halozyme jumps as Q1 results, $1B buyback authorization, and new partnership updates lift sentiment - Quiver Quantitative
Morgan Stanley Cuts Halozyme Therapeutics (NASDAQ:HALO) Price Target to $93.00 - MarketBeat
Halozyme Q1 Beat Driven by Royalty Outperformance, Strong Demand, Morgan Stanley - marketscreener.com
Halozyme Therapeutics Shares Jumping 8.1% on Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and … - AlphaStreet
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2026 Earnings Call Transcript - Insider Monkey
Citizens reiterates Halozyme stock rating on strong Q1 results By Investing.com - Investing.com Nigeria
Morgan Stanley Cuts Price Target on Halozyme Therapeutics to $93 From $96, Keeps Overweight Rating - marketscreener.com
Citizens reiterates Halozyme stock rating on strong Q1 results - Investing.com
Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlight - GuruFocus
TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $96 - Moomoo
HALO Maintained by Morgan Stanley -- Price Target Lowered to $93 - GuruFocus
Halozyme Therapeutics (HALO) Reports Strong Q1 2026 Earnings and Growth Outlook - GuruFocus
Halozyme Therapeutics Q1 Earnings Call Highlights - Inkl
Halozyme Q1 2026 slides: revenue surges 42%, $1B buyback unveiled - Investing.com Canada
Halozyme Reports Strong Q1 2026 Earnings and Strategic Outlook - Intellectia AI
Halozyme (HALO) Q1 2026 Earnings Transcript - AOL.com
Halozyme Therapeutics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HALO) 2026-05-11 - Seeking Alpha
Halozyme Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
H.C. Wainwright Bullish on Halozyme Therapeutics, Inc. (HALO) Commercial Revenue Outlook - Insider Monkey
HALO Posts Strong Q1 Results and Announces $1B Share Repurchase Program - GuruFocus
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises By Investing.com - Investing.com Nigeria
Earnings call transcript: Halozyme Q1 2026 sees strong earnings, stock rises - Investing.com
MSN Money - MSN
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback - ChartMill
Halozyme beats Q1 expectations, but guidance trails estimates By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (HALO) Releases Q1 2026 Earnings: Revenue Beats Estimates but EPS Miss - Quiver Quantitative
HALOZYME THERAPEUTICS ($HALO) Releases Q1 2026 Earnings - Quiver Quantitative
Q1 2026 Halozyme Therapeutics Inc Earnings Call Transcript - GuruFocus
0.71%
자본화:
|
볼륨(24시간):